Live webinar presentation by Moderna's Mike Mullette, Vice President, North America, Commercial Operations and his team. We'll dive into how Moderna is using science and supply chain to end the COVID-19 pandemic with a behind the scenes look at the development of the COVID-19 vaccine; supply chain distribution at an incredible scale; and what Moderna is doing to help overcome lingering hesitancy.

Watch the Virtual Presentation

This presentation is available to RILA Retail Members Only. Please log in to access.

Watch Virtual Presentation

Your Presenter

Michael Mullette

Vice President North America Commercial Operations, Moderna

Michael comes to Moderna with almost 20 years of experience in the vaccines and pharmaceutical sectors around the world. Today, he is responsible for leading the commercial operations for Moderna in the United States and Canada.

He first joined industry with Sanofi Pasteur in 2001 in the US, and subsequently held positions of increasing responsibility in commercial operations and general management in the U.S., Australia, France, Japan, and Canada.

During his tenure in Japan, Michael assumed the chairmanship of the PhRMA Japan Vaccine Committee and contributed valuable insight and perspective on immunization in the country. In September 2018, Michael returned to North America, and was appointed President and CEO of Sanofi Canada and was a member of the board of directors at Innovative Medicines Canada (IMC).

Michael holds a Masters of Business Administration from Lehigh University and a Bachelor of Science degree in Marketing from Villanova University.

Thank You to our Thought Leader and Sponsor

Moderna

www.modernatx.com

Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world-class team. Our pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials underway with other development candidates progressing toward the clinic. In addition, we have numerous discovery programs advancing toward development.